Evidence map›Paper›PMID 31717866›Full record

ArticlePharmaceuticals (Basel, Switzerland)2019

Hydroxypyridinone-Diamine Hybrids as Potential Neuroprotective Agents in the PC12 Cell-Line Model of Alzheimer's Disease.

Elodie Lohou, N André Sasaki, Agnès Boullier, Marine Duplantier, Pascal Sonnet

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elodie LohouAGIR, EA-4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France.
N André SasakiAGIR, EA-4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France.
Agnès BoullierMP3CV, EA-7517, CURS, Amiens University Hospital, 80054 Amiens, France.
Marine DuplantierAGIR, EA-4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France.
Pascal SonnetAGIR, EA-4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France.ORCID 0000-0003-0118-9151

Funding

Région Hauts-de-France 2018SATT Nord SeaPal
6 · The paper itself

Abstract

There is an urgent need to propose effective treatments for Alzheimer's disease (AD). Although the origin of the disease is poorly understood, several therapeutic options have been proposed. The new therapeutic approaches targeting biometal-mediated neurodegenerative pathways appear to be interesting ones. As a continuation of our preceding studies, two novel series of advanced glycation endproducts (AGE)/advanced lipid peroxidation endproducts (ALE) inhibitors have been developed as multifunctional scavengers. This extended work allowed us to highlight the new hydroxypyridinone-diamine hybrid

Indexed as

AGE inhibitorsAlzheimer’s diseasebiometalshydroxypyridinoneoxidative stressvicinal diamine

Identifiers

PMID31717866
PMCPMC6958408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.